Peptides for appetite control
DNF-10® is a hydrolysate fraction from Saccharomyces cerevisiae which acts on the gut-brain mediators of satiety, to lower calorie intake and reduce body fat mass. Benefits demonstrated after the first weeks. Supported with 4 published clinical trials. 500 mg/day.
DNF-10® - Key features
-
Patented ingredient
-
Demonstrated mechanism of action: gut-brain axis moderation of the appetite
-
Significant reduction of calorie intake after first weeks of supplementation
-
Significant weight loss after the first month
-
The weight lost is from fat mass
-
Abdominal fat and waist circumference decrease significantly
Science supporting DNF-10®
More than 10 years of research have been conducted to support the mechanism of action and clinical benefits of DNF-10® on body composition. The mechanism of action of DNF-10® on the mediator of satiety has been studied in vivo in animal models. The reduction of food intake and improvement of body composition have been confirmed with interventional human clinical trials.
More than 10 articles supporting the mechanism of action and health benefits of DNF-10® have been published.
Process & characterisation
DNF-10® is an active fraction produced by the protein hydrolysis of Saccharomyces cerevisiae, a yeast species used for thousands of years in baking, fermented food and beverage manufacturing processes.
The manufacturing of DNF-10® involves enzymatic proteolysis and the use of ultrafiltration to select peptides with a molecular weight <10 kDa. The material is then spray-dried to obtain a dried powder.
Active compounds:
Patented yeast protein hydrolysate from Saccharomyces cerevisiae
Strain NBRC (ex. IFO) 2346
Peptide size: <10 kDa
Composition: Saccharomyces cerevisiae extract.
Recommended daily dosage: from 500 mg
Mechanism of action
DNF-10® acts on the gut-brain axis by regulating the mediators of appetite
Mechanistic studies highlighted that DNF-10® plays a role in regulating serum levels of the appetite hormone ghrelin.
DNF-10® helps to maintain the release of the satiety hormone, leptin, from the adipocyte.
The action of DNF-10® on these 2 hormones leads to a reduction in the secretion of the neuropeptide and appetite neuromediator Y (NPY).
_____________________________________
Mechanistic studies
Animal model
- DNF-10® significantly lowers ghrelin secretion.
- DNF-10® significantly lowers the expression of NPY in the hypothalamus.
- The effect of DNF-10® on decreasing food intake is rapid.
Clinically supported benefits
Double-blind, randomised, placebo-controlled clinical studies.
| YEAR & DURATION | 2014 10 weeks |
2017 |
| POPULATIONS |
54 subjects |
30 subjects Women BMI> 25 kg/m2 Age: 20-60 years old |
| PROTOCOLS |
Abdominal fat distribution No specific exercise and diet patterns |
Body composition No specific exercise and diet patterns |
| INTAKES | SACHETS 2 x 500 mg/day |
CAPSULES 2 x 250 mg/day |
Satiety enhancer
- Subjects taking DNF-10® supplements decrease their caloric intake significantly after the first weeks of supplementation.
- After 2 months, the daily caloric intake drops by 600 kcal.
- All 3 groups of macronutrients are significantly impacted: subjects reduce the number of calories from lipids, proteins, and carbohydrates.
- After a few weeks of consuming DNF-10®, subjects have a reduced appetite for sweet foods.
Body weight loss
Weight loss is significant after one month of supplementation with DNF-10®. Moreover, 100% of the weight lost is from fat mass, leading to a 6% reduction in the fat mass ratio.
Abdominal fat reduction
The change in body composition is confirmed by computed tomography. The subjects’ total abdominal fat mass is significantly reduced by 5% with DNF-10®. Waist circumference is reduced by 5 cm after supplementation.
DNF-10® is safe
No adverse event linked to DNF-10® supplementation has been recorded.
Regulatory & Applications
GRAS self-affirmed with FDA notification GRN1033
Non-GMO project certified, Halal, gluten-free, suitable for vegetarians
Stability validated after heat treatment at 160°C/320°F for 30 min
References
CLINICAL TRIALS
Hong K. et al.; Progr. Nutr., 2015, 17:3:262-264
Jung E. et al.; Phytother. Res., 2009, 3(5):619-23
Jung E. et al.; Nutrition; 2014, 30:25-32
Jung E. et al.; Prev. Nutr. Food Sci.; 2017, 22(1):45-49
MECHANISTIC STUDIES
Park Y. et al.; Food Chemistry, 2013
Jung E.Y. et al., Ann. Nutr. Metab. 2012; 61(2):89-94
Jung E.Y. et al.; Journal of Health Science, 2011; 57(6), 532-539
This website is intended to provide information about Fytexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.
